Go Deep
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,341 | -2.8 | 1.62 | 0.37 | 655.21 |
| Oct 2026 | 22,411 | -2.7 | 1.56 | 0.37 | 625.70 |
| Oct 2026 | 22,246 | -3.1 | 1.72 | 0.37 | 690.37 |
| Oct 2026 | 22,382 | -2.7 | 1.58 | 0.37 | 635.54 |
| Oct 2026 | 22,396 | -2.7 | 1.57 | 0.37 | 630.53 |
| Oct 2026 | 22,406 | -2.7 | 1.56 | 0.37 | 626.74 |
| Oct 2026 | 22,583 | -2.4 | 1.39 | 0.37 | 556.14 |
| Oct 2026 | 22,522 | -2.5 | 1.45 | 0.37 | 578.62 |
| Oct 2026 | 22,571 | -2.4 | 1.40 | 0.37 | 562.06 |
Capricor Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -40,733,654.0 | -33,941,345.0 | -30,170,914.0 | -24,570,647.0 |
| EPS | -0.7 | -0.6 | -0.6 | -0.5 |
Capricor Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 22,270,465.0 | 25,178,066.0 | 2,551,469.0 | — |
| Net Profit | -105,043,946.0 | -40,467,186.0 | -22,287,542.0 | -29,019,532.0 | — |
| EPS | -2.3 | -1.1 | -0.8 | -1.2 | — |
Capricor Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 355,949,294.0 | 170,481,086.0 | 58,734,327.0 | 50,094,910.0 | — |
| Total Liabilities | 50,157,149.0 | 25,018,750.0 | 36,132,860.0 | 38,308,816.0 | — |
| Total Equity | 305,792,145.0 | 145,462,336.0 | 22,601,467.0 | 11,786,094.0 | — |
Owes vs Owns
Capricor Therapeutics, Inc. owed $0.33 for every $1 it owned in Jun 2026, down from $0.76 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.33× | 0.14× | 0.15× | 0.62× | 0.76× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Capricor Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 89.4%Fixed assets (tangible) 8.9%Other assets 1.7%
How it's funded — Dec 2025
Long-term debt 4.0%Other liabilities 9.5%Shareholders' equity 85.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 318.1 | 151.5 | 39.5 | 41.4 |
| Receivables | 0.1 | 10.4 | 10.4 | 0.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 31.9 | 6.9 | 7.6 | 6.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 5.9 | 1.7 | 1.3 | 1.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.8 | 0.7 | 0.7 |
| Long-term debt | 14.3 | 0.6 | 1.5 | 1.9 |
| Payables | 1.7 | 3.3 | 6.2 | 4.8 |
| Other liabilities | 34.0 | 20.3 | 27.7 | 30.9 |
| Shareholders' equity | 305.8 | 145.5 | 22.6 | 11.8 |
| Net tangible assets | 305.8 | 145.5 | 22.6 | 11.8 |
Capricor Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -69,811,261.0 | -39,995,742.0 | -25,596,545.0 | 4,916,637.0 | — |
| Investing Activities | 97,479,281.0 | -116,183,868.0 | 5,108,210.0 | -35,072,507.0 | — |
| Financing Activities | 248,892,296.0 | 152,771,749.0 | 25,579,950.0 | 4,873,838.0 | — |